Janux Therapeutics (JANX) Projected to Announce Earnings on Thursday

Janux Therapeutics (NASDAQ:JANX) is anticipated to announce its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.4737) per share and revenue of $8.03 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Friday, November 13, 2026 at 4:00 PM ET.

Janux Therapeutics (NASDAQ:JANX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.35) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.10). The company had revenue of $10.27 million for the quarter, compared to the consensus estimate of $19.07 million. On average, analysts expect Janux Therapeutics to post ($1.70) EPS for the current fiscal year and ($2.64) EPS for the next fiscal year.

Janux Therapeutics Stock Performance

Janux Therapeutics stock opened at $17.82 on Wednesday. Janux Therapeutics has a fifty-two week low of $12.12 and a fifty-two week high of $35.34. The firm’s 50-day simple moving average is $17.58 and its 200 day simple moving average is $15.36. The stock has a market cap of $1.09 billion, a PE ratio of -10.87 and a beta of 2.44.

Wall Street Analyst Weigh In

Several research firms have commented on JANX. Guggenheim dropped their target price on shares of Janux Therapeutics from $58.00 to $55.00 and set a “buy” rating on the stock in a research report on Friday, August 7th. Wolfe Research upgraded Janux Therapeutics from a “peer perform” rating to an “outperform” rating and set a $23.00 target price on the stock in a research note on Monday, August 24th. TD Cowen upgraded Janux Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Stifel Nicolaus set a $35.00 target price on Janux Therapeutics in a report on Friday, August 7th. Finally, HC Wainwright reaffirmed a “buy” rating on shares of Janux Therapeutics in a report on Monday, October 19th. One equities research analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, two have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average price target of $36.46.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc is a clinical-stage biopharmaceutical company developing immune-based medicines for the treatment of cancer and autoimmune diseases. The company’s research is focused on designing therapies that selectively activate the immune system in diseased tissue while limiting activity in healthy tissue.

Janux’s proprietary technology platform is designed to create tumor-activated T-cell engager therapies and other immunomodulators. These medicines are engineered to remain relatively inactive in the circulation and become activated in the tumor microenvironment, with the goal of improving the therapeutic window of immune therapies.